相关产品推荐更多 >

KRT19 Rabbit Polyclonal Antibody 抗体,orb2955590,Biorbyt
¥2925
GFRA3 Antibody (Center) 抗体,orb1435516,Biorbyt
¥2106
OR2A42 Rabbit Polyclonal Antibody (Biotin) 抗体,orb2085697,Biorbyt
¥0
ATRX Rabbit Polyclonal Antibody 抗体,orb1974731,Biorbyt
¥3159
DNA polymerase subunit II Rabbit Polyclonal Antibody 抗体,orb312823,Biorbyt
¥3159
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
源叶现货试剂/标准品,库存足,周末发货Cytoscape 教程来了!快速实现顶刊同款通路网络图五大应用案例:Mustang Q 膜层析应用全解析1 个小工具,一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 抗体名:
EGFR Antibody 抗体
- 抗体英文名:
EGFR Antibody
- 靶点:
EGFR (HGNC:3236)
- 应用范围:
FC, IHC, WB
- 宿主:
Mouse
- 适应物种:
Human
- 保质期:
12 months from date of receipt.
- 抗原来源:
详询
- 目录编号:
orb1788107
- 级别:
科研
- 库存:
99
- 供应商:
Biorbyt
- 标记物:
Unconjugated
- 克隆性:
Monoclonal
- 保存条件:
详询
- 形态:
Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS.
- 亚型:
IgG1κ
- 免疫原:
详询
产品子类型: Primary Antibody
描述: Purified Mouse Monoclonal Antibody (Mab)
别名: Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, EGFR, ERBB, ERBB1, HER1
应用稀释比例: WB: 1:1000, IHC: 1:25, IHC: 1:25, FC: 1:25
免疫原: Purified His-tagged EGFR protein(Fragment) was used to produced this monoclonal antibody. Antigen Region: 49-299 aa.
分子量: 134277 Da
UniProt ID: P00533
NCBI 参考序列: NP_958441.1, NP_958439.1, NP_958440.1, NP_005219.2
保存条件: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles
备注: For research use only.




风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验will elucidate the relationship of EGFR and tumor、the progession of monocolonal antibody in tumor therapy.【key words】 Epidermal Growth Factor Receptor monocolonal antibody tumor thearpy单克隆抗体治疗是近年来兴起的一项治疗肿瘤的方法,其高均一性、高特异性和安全的特点给肿瘤治疗带来了新希望。表皮生长因子受体(EGFR)表达于多种肿瘤
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
Nature 综述导读:FDA 批准第 100 个抗体药物!抗体药物的研究方向在哪里?
仍超过 50 亿美元。 图七 Journal of Biomedical Science (2020) 27:1来自抗体协会 (Antibody Society) 的数据显示,临床管道中也存在类似的大量内卷现象。目前有将近 870 种抗体在临床开发中,但其中大约 36% 的抗体集中在下表二的 10 个靶点中。PD1/PDL1、HER2、CTLA4、EGFR 和 CD20 仍然占据较高的比例。 表二:Nature Reviews Drug Discovery 20, 10 (2021)癌症将继续占据
技术资料暂无技术资料 索取技术资料






